Augmented Pulmonary Vasoconstrictor Reactivity after Chronic Hypoxia Requires Src Kinase and Epidermal Growth Factor Receptor Signaling
Chronic hypoxia augments pressure- and agonist-induced pulmonary vasoconstriction through myofilament calcium sensitization. NADPH oxidases contribute to the development of pulmonary hypertension, and both epidermal growth factor receptor and Src kinases can regulate NADPH oxidase. We tested the hyp...
Gespeichert in:
Veröffentlicht in: | American journal of respiratory cell and molecular biology 2020-01, Vol.62 (1), p.61-73 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 73 |
---|---|
container_issue | 1 |
container_start_page | 61 |
container_title | American journal of respiratory cell and molecular biology |
container_volume | 62 |
creator | Norton, Charles E Sheak, Joshua R Yan, Simin Weise-Cross, Laura Jernigan, Nikki L Walker, Benjimen R Resta, Thomas C |
description | Chronic hypoxia augments pressure- and agonist-induced pulmonary vasoconstriction through myofilament calcium sensitization. NADPH oxidases contribute to the development of pulmonary hypertension, and both epidermal growth factor receptor and Src kinases can regulate NADPH oxidase. We tested the hypothesis that Src-epidermal growth factor receptor (EGFR) signaling mediates enhanced vasoconstrictor sensitivity after chronic hypoxia through NADPH oxidase-derived superoxide generation. Protocols employed pharmacological inhibitors in isolated, pressurized rat pulmonary arteries to examine the contribution of a variety of signaling moieties to enhanced vascular tone after chronic hypoxia. Superoxide generation in pulmonary arterial smooth muscle cells was assessed using the fluorescent indicator dihydroethidium. Indices of pulmonary hypertension were measured in rats treated with the EGFR inhibitor gefitinib. Inhibition of NADPH oxidase, Rac1 (Ras-related C3 botulinum toxin substrate 1), and EGFR abolished pressure-induced pulmonary arterial tone and endothelin-1 (ET-1)-dependent calcium sensitization and vasoconstriction after chronic hypoxia. Consistently, chronic hypoxia augmented ET-1-induced superoxide production through EGFR signaling, and rats treated chronically with gefitinib displayed reduced right ventricular pressure and diminished arterial remodeling. Src kinases were also activated by ET-1 after chronic hypoxia and contributed to enhanced basal arterial tone and vasoconstriction in response to ET-1. A role for matrix metalloproteinase 2 to mediate Src-dependent EGFR activation is further supported by our findings. Our studies support a novel role for an Src kinase-EGFR-NADPH oxidase signaling axis to mediate enhanced pulmonary vascular smooth muscle Ca
sensitization, vasoconstriction, and pulmonary hypertension after chronic hypoxia. |
doi_str_mv | 10.1165/rcmb.2018-0106oc |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6938133</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2352361206</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-f68c9ccb0bbc2573d00f1d02b0af5143d814404a7684433d4fa254a4d8ef81ca3</originalsourceid><addsrcrecordid>eNpdkU1v1DAQhi0EoqVw54QsceGS1uOPNLkgVat-ICq1osDVmjjOrqvETu2ksL-Av42jbivoySP5mVfz6iHkPbBDgFIdRTM0h5xBVTBgZTAvyD4ooQpZV_XLPDMpC1Cy3iNvUrplDHgF8JrsCeClrBnskz8n83qwfrItvZ77IXiMW_oTUzDBpyk6M4VIv1k0k7t305ZiN9lIV5sYvDP0YjuG3w4zcDe7aBO9iYZ-dR6Tpehbejq61sYBe3oew69pQ89wF2jsuAw3bu2xd379lrzqsE_23e49ID_OTr-vLorLq_Mvq5PLwuR7p6IrK1Mb07CmMVwdi5axDlrGG4adAinaCqRkEo_LSkohWtkhVxJlW9muAoPigHx-yB3nZrCtydUj9nqMbsjNdUCn___xbqPX4V6XtahAiBzwaRcQw91s06QHl4zte_Q2zElzrgA4U1Bm9OMz9DbMMffNlFBclJlbKPZAmRhSirZ7OgaYXizrxbJeLOvF8tUqr3z4t8TTwqNW8Rd5bKdP</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2352361206</pqid></control><display><type>article</type><title>Augmented Pulmonary Vasoconstrictor Reactivity after Chronic Hypoxia Requires Src Kinase and Epidermal Growth Factor Receptor Signaling</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Norton, Charles E ; Sheak, Joshua R ; Yan, Simin ; Weise-Cross, Laura ; Jernigan, Nikki L ; Walker, Benjimen R ; Resta, Thomas C</creator><creatorcontrib>Norton, Charles E ; Sheak, Joshua R ; Yan, Simin ; Weise-Cross, Laura ; Jernigan, Nikki L ; Walker, Benjimen R ; Resta, Thomas C</creatorcontrib><description>Chronic hypoxia augments pressure- and agonist-induced pulmonary vasoconstriction through myofilament calcium sensitization. NADPH oxidases contribute to the development of pulmonary hypertension, and both epidermal growth factor receptor and Src kinases can regulate NADPH oxidase. We tested the hypothesis that Src-epidermal growth factor receptor (EGFR) signaling mediates enhanced vasoconstrictor sensitivity after chronic hypoxia through NADPH oxidase-derived superoxide generation. Protocols employed pharmacological inhibitors in isolated, pressurized rat pulmonary arteries to examine the contribution of a variety of signaling moieties to enhanced vascular tone after chronic hypoxia. Superoxide generation in pulmonary arterial smooth muscle cells was assessed using the fluorescent indicator dihydroethidium. Indices of pulmonary hypertension were measured in rats treated with the EGFR inhibitor gefitinib. Inhibition of NADPH oxidase, Rac1 (Ras-related C3 botulinum toxin substrate 1), and EGFR abolished pressure-induced pulmonary arterial tone and endothelin-1 (ET-1)-dependent calcium sensitization and vasoconstriction after chronic hypoxia. Consistently, chronic hypoxia augmented ET-1-induced superoxide production through EGFR signaling, and rats treated chronically with gefitinib displayed reduced right ventricular pressure and diminished arterial remodeling. Src kinases were also activated by ET-1 after chronic hypoxia and contributed to enhanced basal arterial tone and vasoconstriction in response to ET-1. A role for matrix metalloproteinase 2 to mediate Src-dependent EGFR activation is further supported by our findings. Our studies support a novel role for an Src kinase-EGFR-NADPH oxidase signaling axis to mediate enhanced pulmonary vascular smooth muscle Ca
sensitization, vasoconstriction, and pulmonary hypertension after chronic hypoxia.</description><identifier>ISSN: 1044-1549</identifier><identifier>ISSN: 1535-4989</identifier><identifier>EISSN: 1535-4989</identifier><identifier>DOI: 10.1165/rcmb.2018-0106oc</identifier><identifier>PMID: 31264901</identifier><language>eng</language><publisher>United States: American Thoracic Society</publisher><subject>Animals ; Calcium ; Chronic illnesses ; Epidermal growth factor ; Epidermal growth factor receptors ; ErbB Receptors - metabolism ; Fluorescent indicators ; Gefitinib ; Hypertension ; Hypertension, Pulmonary - drug therapy ; Hypertension, Pulmonary - metabolism ; Hypoxia ; Hypoxia - drug therapy ; Hypoxia - metabolism ; Inhibitor drugs ; Kinases ; Lung - drug effects ; Lung - metabolism ; Male ; Muscle, Smooth, Vascular - drug effects ; Muscle, Smooth, Vascular - metabolism ; Myocytes, Smooth Muscle ; NAD(P)H oxidase ; Original Research ; Pulmonary artery ; Pulmonary Artery - drug effects ; Pulmonary Artery - metabolism ; Pulmonary hypertension ; Rats ; Rats, Sprague-Dawley ; Signal Transduction - drug effects ; Smooth muscle ; src-Family Kinases - metabolism ; Superoxide ; Vasoconstriction ; Vasoconstriction - drug effects ; Vasoconstrictor Agents - pharmacokinetics</subject><ispartof>American journal of respiratory cell and molecular biology, 2020-01, Vol.62 (1), p.61-73</ispartof><rights>Copyright American Thoracic Society Jan 2020</rights><rights>Copyright © 2020 by the American Thoracic Society 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-f68c9ccb0bbc2573d00f1d02b0af5143d814404a7684433d4fa254a4d8ef81ca3</citedby><cites>FETCH-LOGICAL-c490t-f68c9ccb0bbc2573d00f1d02b0af5143d814404a7684433d4fa254a4d8ef81ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31264901$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Norton, Charles E</creatorcontrib><creatorcontrib>Sheak, Joshua R</creatorcontrib><creatorcontrib>Yan, Simin</creatorcontrib><creatorcontrib>Weise-Cross, Laura</creatorcontrib><creatorcontrib>Jernigan, Nikki L</creatorcontrib><creatorcontrib>Walker, Benjimen R</creatorcontrib><creatorcontrib>Resta, Thomas C</creatorcontrib><title>Augmented Pulmonary Vasoconstrictor Reactivity after Chronic Hypoxia Requires Src Kinase and Epidermal Growth Factor Receptor Signaling</title><title>American journal of respiratory cell and molecular biology</title><addtitle>Am J Respir Cell Mol Biol</addtitle><description>Chronic hypoxia augments pressure- and agonist-induced pulmonary vasoconstriction through myofilament calcium sensitization. NADPH oxidases contribute to the development of pulmonary hypertension, and both epidermal growth factor receptor and Src kinases can regulate NADPH oxidase. We tested the hypothesis that Src-epidermal growth factor receptor (EGFR) signaling mediates enhanced vasoconstrictor sensitivity after chronic hypoxia through NADPH oxidase-derived superoxide generation. Protocols employed pharmacological inhibitors in isolated, pressurized rat pulmonary arteries to examine the contribution of a variety of signaling moieties to enhanced vascular tone after chronic hypoxia. Superoxide generation in pulmonary arterial smooth muscle cells was assessed using the fluorescent indicator dihydroethidium. Indices of pulmonary hypertension were measured in rats treated with the EGFR inhibitor gefitinib. Inhibition of NADPH oxidase, Rac1 (Ras-related C3 botulinum toxin substrate 1), and EGFR abolished pressure-induced pulmonary arterial tone and endothelin-1 (ET-1)-dependent calcium sensitization and vasoconstriction after chronic hypoxia. Consistently, chronic hypoxia augmented ET-1-induced superoxide production through EGFR signaling, and rats treated chronically with gefitinib displayed reduced right ventricular pressure and diminished arterial remodeling. Src kinases were also activated by ET-1 after chronic hypoxia and contributed to enhanced basal arterial tone and vasoconstriction in response to ET-1. A role for matrix metalloproteinase 2 to mediate Src-dependent EGFR activation is further supported by our findings. Our studies support a novel role for an Src kinase-EGFR-NADPH oxidase signaling axis to mediate enhanced pulmonary vascular smooth muscle Ca
sensitization, vasoconstriction, and pulmonary hypertension after chronic hypoxia.</description><subject>Animals</subject><subject>Calcium</subject><subject>Chronic illnesses</subject><subject>Epidermal growth factor</subject><subject>Epidermal growth factor receptors</subject><subject>ErbB Receptors - metabolism</subject><subject>Fluorescent indicators</subject><subject>Gefitinib</subject><subject>Hypertension</subject><subject>Hypertension, Pulmonary - drug therapy</subject><subject>Hypertension, Pulmonary - metabolism</subject><subject>Hypoxia</subject><subject>Hypoxia - drug therapy</subject><subject>Hypoxia - metabolism</subject><subject>Inhibitor drugs</subject><subject>Kinases</subject><subject>Lung - drug effects</subject><subject>Lung - metabolism</subject><subject>Male</subject><subject>Muscle, Smooth, Vascular - drug effects</subject><subject>Muscle, Smooth, Vascular - metabolism</subject><subject>Myocytes, Smooth Muscle</subject><subject>NAD(P)H oxidase</subject><subject>Original Research</subject><subject>Pulmonary artery</subject><subject>Pulmonary Artery - drug effects</subject><subject>Pulmonary Artery - metabolism</subject><subject>Pulmonary hypertension</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Signal Transduction - drug effects</subject><subject>Smooth muscle</subject><subject>src-Family Kinases - metabolism</subject><subject>Superoxide</subject><subject>Vasoconstriction</subject><subject>Vasoconstriction - drug effects</subject><subject>Vasoconstrictor Agents - pharmacokinetics</subject><issn>1044-1549</issn><issn>1535-4989</issn><issn>1535-4989</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1v1DAQhi0EoqVw54QsceGS1uOPNLkgVat-ICq1osDVmjjOrqvETu2ksL-Av42jbivoySP5mVfz6iHkPbBDgFIdRTM0h5xBVTBgZTAvyD4ooQpZV_XLPDMpC1Cy3iNvUrplDHgF8JrsCeClrBnskz8n83qwfrItvZ77IXiMW_oTUzDBpyk6M4VIv1k0k7t305ZiN9lIV5sYvDP0YjuG3w4zcDe7aBO9iYZ-dR6Tpehbejq61sYBe3oew69pQ89wF2jsuAw3bu2xd379lrzqsE_23e49ID_OTr-vLorLq_Mvq5PLwuR7p6IrK1Mb07CmMVwdi5axDlrGG4adAinaCqRkEo_LSkohWtkhVxJlW9muAoPigHx-yB3nZrCtydUj9nqMbsjNdUCn___xbqPX4V6XtahAiBzwaRcQw91s06QHl4zte_Q2zElzrgA4U1Bm9OMz9DbMMffNlFBclJlbKPZAmRhSirZ7OgaYXizrxbJeLOvF8tUqr3z4t8TTwqNW8Rd5bKdP</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Norton, Charles E</creator><creator>Sheak, Joshua R</creator><creator>Yan, Simin</creator><creator>Weise-Cross, Laura</creator><creator>Jernigan, Nikki L</creator><creator>Walker, Benjimen R</creator><creator>Resta, Thomas C</creator><general>American Thoracic Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202001</creationdate><title>Augmented Pulmonary Vasoconstrictor Reactivity after Chronic Hypoxia Requires Src Kinase and Epidermal Growth Factor Receptor Signaling</title><author>Norton, Charles E ; Sheak, Joshua R ; Yan, Simin ; Weise-Cross, Laura ; Jernigan, Nikki L ; Walker, Benjimen R ; Resta, Thomas C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-f68c9ccb0bbc2573d00f1d02b0af5143d814404a7684433d4fa254a4d8ef81ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Calcium</topic><topic>Chronic illnesses</topic><topic>Epidermal growth factor</topic><topic>Epidermal growth factor receptors</topic><topic>ErbB Receptors - metabolism</topic><topic>Fluorescent indicators</topic><topic>Gefitinib</topic><topic>Hypertension</topic><topic>Hypertension, Pulmonary - drug therapy</topic><topic>Hypertension, Pulmonary - metabolism</topic><topic>Hypoxia</topic><topic>Hypoxia - drug therapy</topic><topic>Hypoxia - metabolism</topic><topic>Inhibitor drugs</topic><topic>Kinases</topic><topic>Lung - drug effects</topic><topic>Lung - metabolism</topic><topic>Male</topic><topic>Muscle, Smooth, Vascular - drug effects</topic><topic>Muscle, Smooth, Vascular - metabolism</topic><topic>Myocytes, Smooth Muscle</topic><topic>NAD(P)H oxidase</topic><topic>Original Research</topic><topic>Pulmonary artery</topic><topic>Pulmonary Artery - drug effects</topic><topic>Pulmonary Artery - metabolism</topic><topic>Pulmonary hypertension</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Signal Transduction - drug effects</topic><topic>Smooth muscle</topic><topic>src-Family Kinases - metabolism</topic><topic>Superoxide</topic><topic>Vasoconstriction</topic><topic>Vasoconstriction - drug effects</topic><topic>Vasoconstrictor Agents - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Norton, Charles E</creatorcontrib><creatorcontrib>Sheak, Joshua R</creatorcontrib><creatorcontrib>Yan, Simin</creatorcontrib><creatorcontrib>Weise-Cross, Laura</creatorcontrib><creatorcontrib>Jernigan, Nikki L</creatorcontrib><creatorcontrib>Walker, Benjimen R</creatorcontrib><creatorcontrib>Resta, Thomas C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of respiratory cell and molecular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Norton, Charles E</au><au>Sheak, Joshua R</au><au>Yan, Simin</au><au>Weise-Cross, Laura</au><au>Jernigan, Nikki L</au><au>Walker, Benjimen R</au><au>Resta, Thomas C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Augmented Pulmonary Vasoconstrictor Reactivity after Chronic Hypoxia Requires Src Kinase and Epidermal Growth Factor Receptor Signaling</atitle><jtitle>American journal of respiratory cell and molecular biology</jtitle><addtitle>Am J Respir Cell Mol Biol</addtitle><date>2020-01</date><risdate>2020</risdate><volume>62</volume><issue>1</issue><spage>61</spage><epage>73</epage><pages>61-73</pages><issn>1044-1549</issn><issn>1535-4989</issn><eissn>1535-4989</eissn><abstract>Chronic hypoxia augments pressure- and agonist-induced pulmonary vasoconstriction through myofilament calcium sensitization. NADPH oxidases contribute to the development of pulmonary hypertension, and both epidermal growth factor receptor and Src kinases can regulate NADPH oxidase. We tested the hypothesis that Src-epidermal growth factor receptor (EGFR) signaling mediates enhanced vasoconstrictor sensitivity after chronic hypoxia through NADPH oxidase-derived superoxide generation. Protocols employed pharmacological inhibitors in isolated, pressurized rat pulmonary arteries to examine the contribution of a variety of signaling moieties to enhanced vascular tone after chronic hypoxia. Superoxide generation in pulmonary arterial smooth muscle cells was assessed using the fluorescent indicator dihydroethidium. Indices of pulmonary hypertension were measured in rats treated with the EGFR inhibitor gefitinib. Inhibition of NADPH oxidase, Rac1 (Ras-related C3 botulinum toxin substrate 1), and EGFR abolished pressure-induced pulmonary arterial tone and endothelin-1 (ET-1)-dependent calcium sensitization and vasoconstriction after chronic hypoxia. Consistently, chronic hypoxia augmented ET-1-induced superoxide production through EGFR signaling, and rats treated chronically with gefitinib displayed reduced right ventricular pressure and diminished arterial remodeling. Src kinases were also activated by ET-1 after chronic hypoxia and contributed to enhanced basal arterial tone and vasoconstriction in response to ET-1. A role for matrix metalloproteinase 2 to mediate Src-dependent EGFR activation is further supported by our findings. Our studies support a novel role for an Src kinase-EGFR-NADPH oxidase signaling axis to mediate enhanced pulmonary vascular smooth muscle Ca
sensitization, vasoconstriction, and pulmonary hypertension after chronic hypoxia.</abstract><cop>United States</cop><pub>American Thoracic Society</pub><pmid>31264901</pmid><doi>10.1165/rcmb.2018-0106oc</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1044-1549 |
ispartof | American journal of respiratory cell and molecular biology, 2020-01, Vol.62 (1), p.61-73 |
issn | 1044-1549 1535-4989 1535-4989 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6938133 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Animals Calcium Chronic illnesses Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - metabolism Fluorescent indicators Gefitinib Hypertension Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - metabolism Hypoxia Hypoxia - drug therapy Hypoxia - metabolism Inhibitor drugs Kinases Lung - drug effects Lung - metabolism Male Muscle, Smooth, Vascular - drug effects Muscle, Smooth, Vascular - metabolism Myocytes, Smooth Muscle NAD(P)H oxidase Original Research Pulmonary artery Pulmonary Artery - drug effects Pulmonary Artery - metabolism Pulmonary hypertension Rats Rats, Sprague-Dawley Signal Transduction - drug effects Smooth muscle src-Family Kinases - metabolism Superoxide Vasoconstriction Vasoconstriction - drug effects Vasoconstrictor Agents - pharmacokinetics |
title | Augmented Pulmonary Vasoconstrictor Reactivity after Chronic Hypoxia Requires Src Kinase and Epidermal Growth Factor Receptor Signaling |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A18%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Augmented%20Pulmonary%20Vasoconstrictor%20Reactivity%20after%20Chronic%20Hypoxia%20Requires%20Src%20Kinase%20and%20Epidermal%20Growth%20Factor%20Receptor%20Signaling&rft.jtitle=American%20journal%20of%20respiratory%20cell%20and%20molecular%20biology&rft.au=Norton,%20Charles%20E&rft.date=2020-01&rft.volume=62&rft.issue=1&rft.spage=61&rft.epage=73&rft.pages=61-73&rft.issn=1044-1549&rft.eissn=1535-4989&rft_id=info:doi/10.1165/rcmb.2018-0106oc&rft_dat=%3Cproquest_pubme%3E2352361206%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2352361206&rft_id=info:pmid/31264901&rfr_iscdi=true |